- Home
- LFCR vs AARD Comparison
LFCR vs AARD Comparison
Compare LFCR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | AARD |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.9M | 165.8M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LFCR | AARD |
|---|---|---|
| Price | $4.65 | $6.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $6.00 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 122.5K | 117.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $557,559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $3.63 | $3.35 |
| 52 Week High | $8.98 | $17.94 |
Technical Indicators
Market Signals| Indicator | LFCR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 51.19 |
| Support Level | $4.63 | $4.99 |
| Resistance Level | $5.21 | $8.02 |
| Average True Range (ATR) | 0.24 | 0.87 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 46.10 | 40.25 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.